![]() ![]() ![]() ![]() Some of the symptoms of an allergic reaction may include: any of the ingredients listed at the end of this leaflet.Before you take Eliquis When you must not take itĭo not take Eliquis if you have an allergy to: There is not enough information to recommend the use of this medicine in children and adolescents under the age of 18 years. This medicine is not expected to affect your ability to drive a car or operate machinery. This medicine is available only with a doctor's prescription. Your doctor may have prescribed it for another reason. It works by inhibiting a blood clot forming substance called Factor Xa.Īsk your doctor if you have any questions about why this medicine has been prescribed for you. It belongs to a group of medicines called antithrombotic agents. The active substance in Eliquis is apixaban. This can lead to blood clots forming and increase your risk of having a stroke. With atrial fibrillation, part of the heart does not beat the way it should. prevent stroke and blood clots in a condition called atrial fibrillation, which is a type of abnormal heart rhythm.treat blood clots occurring in deep veins (Deep Vein Thrombosis ) and clots in your lungs (Pulmonary Embolism ) and also to prevent these from recurring.prevent blood clots in your veins after a hip or knee replacement surgery.Īfter an operation you are at an increased risk of getting blood clots.What Eliquis is used for What Eliquis does If you have any concerns about taking this medicine, ask your doctor or pharmacist. Your doctor has weighed the risks of you taking Eliquis against the benefits it is expected to have for you. It does not take the place of talking to your doctor or pharmacist.Īll medicines have risks and benefits. It does not contain all the available information. All rights reserved.This leaflet answers some common questions about Eliquis. This review article summarizes pharmacological characteristics of these novel antidotes, coagulation's tests affected, available clinical and preclinical data, and the need for phase III and IV studies.ĪNNEXA-A ANNEXA-R Andexanet alfa Antidote Apixaban DOAC Dabigatran Edoxaban Idarucizumab NOAC Praxbind Rivaroxaban.Ĭopyright © 2016 Elsevier Ireland Ltd. Aripazine (PER-977), the third reversal agent, has shown promising activity against dabigatran, apixaban, rivaroxaban, as well as subcutaneous fondaparinux and LMWH. It is currently being studied in ANNEXA-4, a phase IV study. Andexanet alfa (PRT064445), a specific reversal agent against factor Xa inhibitors, showed a complete reversal of anticoagulant activity of apixaban and rivaroxaban within minutes after administration without adverse effects in two recently completed parallel phase III trials ANNEXA-A and ANNEXA-R respectively. A phase III trial on Idarucizumab also complete reversal of anticoagulant effect of dabigatran. It comprehensively reversed dabigatran-induced anticoagulation in a phase I study. Idarucizumab, the first novel antidote against direct thrombin inhibitor dabigatran was approved by US FDA in October 2015. Activated charcoal, hemodialysis, and activated Prothrombin Complex Concentrate (PCC) were amongst the nonspecific agents used in a DOAC associated bleeding but with limited success. However, the biggest drawback of DOACs has been the lack of specific antidotes to reverse the anticoagulant effect in emergency situations. DOACs have many advantages over warfarin. Direct thrombin inhibitor: dabigatran and factor Xa inhibitors: apixaban, rivaroxaban, and edoxaban directly inhibit the coagulation cascade. The Vitamin K antagonist warfarin was the only oral anticoagulant available for decades for the treatment of thrombosis and prevention of thromboembolism until Direct Oral Anticoagulants (DOACs) a group of new oral anticoagulants got approved in the last few years. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |